HALO forecasts over $1 billion in royalties from ENHANZE partnerships by 2026 and launches a $1 billion share repurchase program.
Halozyme Therapeutics expects ENHANZE royalties to exceed $1 billion in 2026, driven by strong partner deal activity and early-stage pipeline progress. The company also announced a new $1 billion share buyback program during its Q1 2026 earnings call.
Management reaffirmed confidence in its 2026-2028 financial guidance, citing momentum in partner collaborations and Phase I trial advancements. The buyback reflects optimism in long-term growth prospects amid robust royalty projections.
No immediate market reaction was disclosed in the earnings call summary.